Modulators of fatty acid amide hydrolase

Patent metadata

Field	Value
Publication number	US-9688664-B2
Application number	US-201414565535-A
Country	US
Kind code	B2
Filing date	Dec 10, 2014
Priority date	May 3, 2010
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is also disclosed.

First claim

What is claimed is:

1. A method of treating a patient suffering from a disorder selected from the group consisting of anxiety, depression and post-traumatic stress disorder comprising administering to said patient a therapeutically effective amount of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 , wherein the disorder is anxiety.

3. A method according to claim 1 , wherein the disorder is depression.

4. A method according to claim 1 , wherein the disorder is post-traumatic stress disorder.

5. A method of treating a patient suffering from a disorder selected from the group consisting of anxiety, depression and post-traumatic stress disorder comprising administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

6. A method according to claim 5 , wherein the disorder is anxiety.

7. A method according to claim 5 , wherein the disorder is depression.

8. A method according to claim 5 , wherein the disorder is post-traumatic stress disorder.

9. A method according to claim 1 wherein the effective amount comprises 0.01 mg/kg per day to 35 mg/kg per day.

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Keith John M
• Liu Jing

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/12

  Antihypertensives · CPC title